Immunogenicity of a DNA prime and recombinant adenovirus boost regime significantly varies between rhesus macaques of Chinese and Indian origins
SCIE
SCOPUS
- Title
- Immunogenicity of a DNA prime and recombinant adenovirus boost regime significantly varies between rhesus macaques of Chinese and Indian origins
- Authors
- Stahl-Hennig, C; Suh, YS; Park, KS; Sauermann, U; Kim, KS; Ahn, S; Franz, M; Schulte, R; Stolt-Leeb, N; Hunsmann, G; Sung, YC
- Date Issued
- 2007-08
- Publisher
- BLACKWELL PUBLISHING
- Abstract
- Background Due to an ever increasing shortage of rhesus macaques of Indian origin (InR) that have been generally used for preclinical AIDS vaccine trials in non-human primates, demand is rising for Chinese rhesus macaques (ChR). However, the immunogenicity of an AIDS vaccine candidate has not been compared in parallel in both rhesus macaque subspecies. Methods ChR and InR were immunized with SIV/HIV DNA and adenovirus vaccine and their immune responses to SIV and HIV evaluated. Results SIV Gag- and Env-specific T-cell responses and SIV-specific lymphoproliferative responses measured in ChR were significantly weaker than those in InR (P < 0.05). By contrast, antibody responses to SIV Env, Tat, and Nef in ChR were stronger than those in InR (P < 0.05). Conclusions Immunogenicity of an AIDS vaccine can vary significantly depending on the geographic origin implying genetic differences of macaques. This must be considered when describing and interpreting results of such vaccine studies.
- Keywords
- AIDS; non-human primates; SIV; vaccine; SIMIAN IMMUNODEFICIENCY VIRUS; T-LYMPHOCYTE RESPONSES; IMMUNE-RESPONSES; VIRAL LOADS; INFECTION; VACCINE; SIVMAC; HIV; AIDS; GAG
- URI
- https://oasis.postech.ac.kr/handle/2014.oak/23243
- DOI
- 10.1111/j.1600-0684.2007.00237.x
- ISSN
- 0047-2565
- Article Type
- Article
- Citation
- JOURNAL OF MEDICAL PRIMATOLOGY, vol. 36, no. 39908, page. 195 - 205, 2007-08
- Files in This Item:
- There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.